LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

Search

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

6.01 1.52

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.97

Max

6.12

Belangrijke statistieken

By Trading Economics

Inkomsten

-38M

-57M

Verkoop

-40M

14M

EPS

-0.66

Winstmarge

-407.067

Werknemers

192

EBITDA

-48M

-65M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+275.42% upside

Dividenden

By Dow Jones

Volgende Winsten

7 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.4M

527M

Vorige openingsprijs

4.49

Vorige sluitingsprijs

6.01

Nieuwssentiment

By Acuity

58%

42%

298 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mei 2025, 23:47 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

18 mei 2025, 23:40 UTC

Marktinformatie

Gold Rises Amid Concerns Over U.S. Fiscal Deficit -- Market Talk

18 mei 2025, 18:00 UTC

Winsten

Tax Bill News; Target, Home Depot, and Snowflake Earnings; and More Stock Market News to Watch This Week -- Barrons.com

18 mei 2025, 17:01 UTC

Top Nieuws

GM Is Fighting California on EVs. This Is What It Wants to Overturn and Why. -- Barrons.com

18 mei 2025, 16:20 UTC

Winsten

Tesla Demand Hasn't Rebounded Yet. Watch China This Week. -- Barrons.com

18 mei 2025, 12:09 UTC

Top Nieuws

Trump Sounds Upbeat on Ukraine Cease-Fire as Russia Unleashes Drone Barrage -- WSJ

17 mei 2025, 17:15 UTC

Top Nieuws

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

17 mei 2025, 09:30 UTC

Top Nieuws
Winsten

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 mei 2025, 08:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 mei 2025, 08:20 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

16 mei 2025, 23:18 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mei 2025, 22:30 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- Update

16 mei 2025, 21:56 UTC

Marktinformatie

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mei 2025, 21:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

16 mei 2025, 21:54 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mei 2025, 21:22 UTC

Marktinformatie

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mei 2025, 21:17 UTC

Marktinformatie

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mei 2025, 21:17 UTC

Top Nieuws

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mei 2025, 21:05 UTC

Marktinformatie

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mei 2025, 20:55 UTC

Acquisities, Fusies, Overnames

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mei 2025, 20:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

16 mei 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 mei 2025, 20:37 UTC

Top Nieuws

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mei 2025, 20:33 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mei 2025, 20:30 UTC

Acquisities, Fusies, Overnames

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mei 2025, 20:18 UTC

Top Nieuws

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mei 2025, 20:16 UTC

Top Nieuws

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mei 2025, 20:15 UTC

Winsten

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mei 2025, 20:11 UTC

Acquisities, Fusies, Overnames

Henry Schein: William K. Daniel Joins Board

16 mei 2025, 20:10 UTC

Acquisities, Fusies, Overnames

Henry Schein: Strategic Investment by KKR Completed

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

275.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22.6 USD  275.42%

Hoogste 40 USD

Laagste 10 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

10

Buy

3

Hold

0

Sell

Technische score

By Trading Central

5.575 / 6.6Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

298 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.